yes, do your DD, the work was published on a decent journal: Cancer Biotherapy & Radiopharmaceuticals https://www.liebertpub.com/doi/10.1089/cbr.2019.2947 This is the milestone of VIVOS, the word is spreading and new investors is buying the shares, there won't lots of cheapies there. when the Reg A funding finishes, RDGL is going much higher level and company will focus on IDE to get human trials started.